A
71.63
0.09 (0.13%)
| Previous Close | 71.54 |
| Open | 71.61 |
| Volume | 1,916,946 |
| Avg. Volume (3M) | 5,192,921 |
| Market Cap | 10,792,902,656 |
| Price / Sales | 451.36 |
| Price / Book | 5.73 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Operating Margin (TTM) | -8,360.90% |
| Diluted EPS (TTM) | -3.00 |
| Quarterly Revenue Growth (YOY) | -55.60% |
| Total Debt/Equity (MRQ) | 0.45% |
| Current Ratio (MRQ) | 16.91 |
| Operating Cash Flow (TTM) | -355.32 M |
| Levered Free Cash Flow (TTM) | -245.73 M |
| Return on Assets (TTM) | -22.47% |
| Return on Equity (TTM) | -34.19% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Avidity Biosciences, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.5
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.50 |
|
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 5.17% |
| % Held by Institutions | 112.41% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ra Capital Management, L.P. | 30 Sep 2025 | 8,641,031 |
| Bellevue Group Ag | 30 Sep 2025 | 2,152,862 |
| Casdin Capital, Llc | 30 Sep 2025 | 1,780,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 74.00 (TD Cowen, 3.31%) | Hold |
| Median | 72.00 (0.52%) | |
| Low | 62.00 (Roth Capital, -13.44%) | Buy |
| Average | 69.36 (-3.17%) | |
| Total | 3 Buy, 8 Hold | |
| Avg. Price @ Call | 62.08 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 11 Nov 2025 | 72.00 (0.52%) | Hold | 70.70 |
| 28 Oct 2025 | 72.00 (0.52%) | Hold | 69.93 | |
| TD Cowen | 29 Oct 2025 | 74.00 (3.31%) | Hold | 69.65 |
| RBC Capital | 28 Oct 2025 | 72.00 (0.52%) | Hold | 69.93 |
| Bernstein | 27 Oct 2025 | 72.00 (0.52%) | Hold | 70.00 |
| Citigroup | 27 Oct 2025 | 72.00 (0.52%) | Hold | 70.00 |
| HC Wainwright & Co. | 27 Oct 2025 | 72.00 (0.52%) | Hold | 70.00 |
| 12 Sep 2025 | 87.00 (21.46%) | Buy | 44.74 | |
| Leerink Partners | 27 Oct 2025 | 72.00 (0.52%) | Hold | 70.00 |
| Needham | 27 Oct 2025 | 65.00 (-9.26%) | Hold | 70.00 |
| 10 Sep 2025 | 65.00 (-9.26%) | Buy | 46.40 | |
| Evercore ISI Group | 22 Sep 2025 | 65.00 (-9.26%) | Buy | 42.34 |
| Roth Capital | 17 Sep 2025 | 62.00 (-13.44%) | Buy | 40.06 |
| B of A Securities | 15 Sep 2025 | 65.00 (-9.26%) | Buy | 40.22 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |